Search

Zentalis Pharmaceuticals Inc

Lezárt

3.07 1.32

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3

Maximum

3.13

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+190.43% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-44M

287M

Előző nyitás

1.75

Előző zárás

3.07

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 22. 23:56 UTC

Correlated Moves

TE Connectivity PLC declined slightly in after-market trading, amid concerns over economic momentum following a drop in the Richmond Fed Manufacturing Index.

2026. szept. 22. 23:56 UTC

Raymond James Financial Inc is trading modestly lower in after-market hours, continuing a decline since Tuesday and remaining near the low end of its one-month range.

2026. szept. 22. 23:56 UTC

Correlated Moves

Hess Midstream LP is trading lower in after-market hours, following a flat session and amid a decline in shares of Targa Resources Corp.

2026. szept. 22. 23:56 UTC

Correlated Moves

Agree Realty Corp is trading slightly higher in after-market hours, influenced by positive earnings reports from consumer discretionary companies.

2026. szept. 22. 23:56 UTC

Plumas Bancorp remains roughly flat in after-market trading, showing little change since Tuesday's close and oscillating around the midpoint of its one-month trading range.

2026. szept. 22. 23:56 UTC

Correlated Moves

Delek US Holdings Inc is trading lower in after-market hours, potentially in sympathy with HF Sinclair Corp, which has also declined.

2026. szept. 22. 23:55 UTC

Andersons Inc is experiencing notable gains in after-market trading, recovering from previous lower closes but remains below its 20-day moving average.

2026. szept. 22. 23:55 UTC

Pentair PLC is trading modestly higher in after-market hours, continuing a gradual increase, though it remains below its 20-day moving average.

2026. szept. 22. 23:55 UTC

Healthequity Inc. is trading modestly lower in after-market hours, continuing a decline from Tuesday's close and remaining below its 20-day moving average.

2026. szept. 22. 23:55 UTC

M&T Bank Corp is trading modestly higher in after-market hours, remaining above its opening level despite a slight pullback during the regular session.

2026. szept. 22. 23:55 UTC

Darling Ingredients Inc is trading modestly lower in after-market hours, continuing a four-session decline and remaining significantly below its 20-day moving average.

2026. szept. 22. 23:55 UTC

News

Roivant Sciences Ltd is higher in after-market trading following positive Phase 2 trial results for mosliciguat, showing significant improvements in pulmonary hypertension patients.

2026. szept. 22. 23:52 UTC

CarMax Inc. is trading modestly lower in after-market hours, continuing a decline since Tuesday's close and remaining below its 20-day moving average.

2026. szept. 22. 23:51 UTC

News

Itron Inc's stock is declining in after-market trading, despite the launch of its Riva IEC Grid Edge Portfolio in the Asia Pacific region.

2026. szept. 22. 23:51 UTC

MACOM Technology Solutions Holdings Inc is up in after-market trading, continuing a trend of seven consecutive higher daily closes and remaining above its 20-day moving average.

2026. szept. 22. 23:51 UTC

Old Dominion Freight Line Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average after a brief rise earlier.

2026. szept. 22. 23:51 UTC

First Solar Inc is trading modestly lower in after-market hours, following a notable dip earlier in the session and remaining below its 20-day moving average.

2026. szept. 22. 23:51 UTC

Eversource Energy is trading modestly higher in after-market hours, despite recent lower performance and positioning below its 20-day moving average.

2026. szept. 22. 23:51 UTC

Nucor Corp is trading modestly lower in after-market hours, continuing a downward trend since Tuesday's close and positioned below its 20-day moving average.

2026. szept. 22. 23:51 UTC

Targa Resources Corp is seeing a modest decline in after-market trading, continuing a trend of three consecutive lower daily closes.

2026. szept. 22. 23:51 UTC

Correlated Moves

SM Energy Co is trading modestly lower in after-market hours, continuing a decline amid concerns from the Richmond Fed Manufacturing Index's unexpected fall.

2026. szept. 22. 23:51 UTC

Brazil's Unemployment Rate Set to Release on September 29, Expected to Reflect Continued Labor Market Improvement Amid Global Economic Concerns.

2026. szept. 22. 23:51 UTC

Australia's S&P Global Services PMI at 51.4 signals slight expansion, but mixed retail forecasts raise concerns about consumer spending ahead of the holiday season.

2026. szept. 22. 23:51 UTC

Australia's S&P Global Manufacturing PMI Flash at 49.3 Signals Contraction, Raising Concerns Over Economic Growth and Potential Monetary Policy Adjustments.

2026. szept. 22. 23:51 UTC

Japan's Industrial Production Report Set for Release on September 29, Amidst Positive Trends and Global Economic Influences.

2026. szept. 22. 23:51 UTC

Japan's Retail Sales Data Release on September 29 Faces Caution Amid Interest Rate Hike and Yen Weakness.

2026. szept. 22. 23:50 UTC

News

Coeur Mining plans a record $158 million exploration investment for 2026, more than double 2025's budget, as shares rise in after-market trading.

2026. szept. 22. 23:50 UTC

Cinemark Holdings Inc is declining in after-market trading, falling from earlier gains and nearing the lower end of its one-month trading range.

2026. szept. 22. 23:50 UTC

Veeva Systems Inc is trading modestly higher in after-hours action, remaining below its 20-day moving average and around the midpoint of its one-month range.

2026. szept. 22. 23:50 UTC

Aspen Aerogels Inc is trading lower in after-market hours, showing a significant decline from Tuesday's close, though still above its 20-day moving average.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

190.43% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.8 USD  190.43%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.